title: Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying β-lactamases prevalent in the United States.
abstract: Contemporary (2012) β-lactamase-producing isolates (n=493) from U.S. hospitals were tested against ceftaroline-avibactam. Klebsiella spp., Escherichia coli and Proteus mirabilis isolates displaying the Clinical and Laboratory Standards Institute (CLSI) screening criteria for extended spectrum β-lactamase (ESBL) production were evaluated. Isolates carried genes encoding CTX-M (n=316, CTX-M-14-like and -15-like), KPC (n=45), CMY-2-like (n=54), or SHV enzyme with ESBL activity (n=78). Ceftaroline-avibactam inhibited 98.2% of the isolates at ≤0.5 μg/mL, and all strains were inhibited by ≤2 μg/mL of this novel β-lactamase-inhibitor combination. These results confirm that ceftaroline-avibactam could be a useful therapeutic option for Enterobacteriaceae isolates producing β-lactamases that are prevalent in the United States.
authors.affiliation: 1 JMI Laboratories , North Liberty, Iowa.
authors.forename: Mariana
authors.initials: M
authors.lastname: Castanheira
authors.forename: Gregory
authors.initials: G
authors.lastname: Williams
authors.forename: Ronald N
authors.initials: RN
authors.lastname: Jones
authors.forename: Helio S
authors.initials: HS
authors.lastname: Sader
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D053961:Azabicyclo Compounds / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D004338:Drug Combinations; D004756:Enterobacteriaceae Infections / Q000453:epidemiology / Q000382:microbiology; D004926:Escherichia coli / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D006801:Humans; D007709:Klebsiella / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D015995:Prevalence; D011513:Proteus mirabilis / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D014481:United States / Q000453:epidemiology; D001618:beta-Lactamases / Q000145:classification / Q000235:genetics; D000097583:Ceftaroline
chemical_list: D000900:Anti-Bacterial Agents; D053961:Azabicyclo Compounds; D002511:Cephalosporins; D004338:Drug Combinations; D001618:beta-Lactamases; D000097583:Ceftaroline; C543519:avibactam